Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President
"We are excited to welcome Tracey to our management team. She brings a wealth of global legal experience and a proven ability to tackle the legal challenges associated with the development and commercialization of medicines for patients suffering from rare diseases," said
Ms. McCain joins
"With preliminary data expected for three Phase 1 clinical trials by year-end, I am thrilled to join the team at this important stage of growth and development," said Ms. McCain. "I believe
About
Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing of preliminary clinical data for
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-appointment-of-tracey-mccain-as-chief-legal-officer-and-executive-vice-president-300322137.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W2O Group, 301-801-5540, rhutman@wcgworld.com